Skip to main content

Table 2 Distribution of lesions

From: Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography

 

Lesions included in the analysis

Histopathological confirmation

(n = 597)

(n = 147)

Tumor type a,b

  

Lung cancer

104

40

Head and neck cancer

61

32

Gastrointestinal cancerc

129

24

Breast cancer

60

6

Lymphoma

125

20

Melanoma

26

10

Multiple melanoma

32

3

Otherd

60

12

Clinical question b

  

Diagnosis

22

10

Staging

20

11

Restaginge

33

18

Response to chemotherapy

58

6

Response to radiotherapy

18

6

Post-surgery evaluation

11

0

Surveillance

40

22

Site of disease b

  

Neck

93

33

Thorax

110

49

Abdomen

220

45

Skeleton-bone marrow

174

20

Lymph nodesf

198

32

  1. Values are mean ± standard deviation.
  2. aTwo patients were not affected by any oncologic disease after histologic confirmation.
  3. bTumor type, clinical questions, and disease sites correspond to the groups submitted to the tumor-based and question-based analyses.
  4. cIncluding esophageal, gastric, and colorectal cancer.
  5. dGynecologic malignancy (n = 8) , testicular cancer (n = 2), sarcoma (n = 3), low-differentiated neuroendocrine carcinoma (n = 4), thymoma (n = 1).
  6. eSuspected relapse or patients with potentially resectable metastatic disease.
  7. fLymph nodes were computed twice: according to their position in the body and independently from their position.